About

Christopher M. Hull, MD, is a professor at the University of Utah Health with specialized expertise in the treatment of autoimmune skin diseases and viral infections of the skin. He is board certified in dermatology and focuses on general dermatology and medical dermatology, including autoimmune blistering diseases. His clinical work is characterized by thoroughness, compassion, and a patient-centered approach, earning high praise from patients for his knowledge, professionalism, and caring demeanor. Dr. Hull is also involved in training medical students and nursing students, demonstrating his commitment to education and the dissemination of current academic knowledge in dermatology.

Research topics

• Medicine
• Dermatology
• Pathology
• Materials science
• Chemistry
• Family medicine
• Anatomy
• Optoelectronics
• Surgery
• Internal medicine

Selected publications

• The role of antibody class and target on subepidermal blistering disease phenotype and management

  Italian Journal of Dermatology and Venereology · 2026-03-01

  articleOpen access

  Subepidermal blistering diseases are driven by autoantibodies targeted to the basement membrane zone. These autoantibodies can stem from multiple antibody classes (e.g., IgE, IgG, IgM, IgA) and differing antibody classes and antibody targets can impact disease phenotype and potentially management. Despite significant advances, there remains a paucity of data and funding for further elucidating subepidermal blistering disease pathophysiology and the impact this has on management. This review highlights current understanding of subepidermal blistering disease antibody targets, classes, and the impact these have on disease clinical phenotype and management. Highlighted conditions will include bullous pemphigoid, mucous membrane pemphigoid, including ocular cicatricial pemphigoid, linear IgA disease, and epidermolysis bullosa acquisita.

  PublisherDOI

• 61425 Comparing Apples to Oranges: Clearance rates of standard excisions of melanoma in situ, squamous cell in situ, and superficial basal cell carcinoma after shave biopsy on the trunk

  Journal of the American Academy of Dermatology · 2025-09-01

  article
  PublisherDOI

• An Allergy-Based Approach to Orofacial Granulomatosis: A Narrative Review

  Dermatitis · 2025-09-19

  article

  The relationship between orofacial granulomatous (OFG) conditions and allergy is evolving. Contact allergies are commonly reported, but the impact of allergy avoidance is unclear, and a current review evaluating this literature has not been performed. We identified 46 studies evaluating the impact of allergen avoidance in OFG (33 case reports, 5 case series, 5 single-arm interventional clinical trials, 1 non-randomized uncontrolled trial, and 2 prospective cohort studies). Patch testing was performed in 158 patients, and the most commonly reported allergens were gold (n = 2), mercury (n = 6), cinnamal/cinnamon (n = 27), sorbic acid (n = 7), grass/silver birch/plant-containing products (n = 22), fragrance (n = 5), nickel (n = 7), and benzoic acid (n = 21). When allergen avoidance was trialed, 123/171 (71%) of patients reported some degree of improvement. A validated scoring/grading system for Granulomatous Cheilitis, Melkerrson-Rosenthal syndrome, and OFG has not been developed, so we were unable to formally assess improvement, instead relying on physician- and patient-reported outcomes in addition to oral disease severity score reporting in several studies. Current literature supports both patch testing and a trial of allergen avoidance/elimination diet to improve OFG in those with a positive result. Few controlled studies have been performed to assess this relationship, and more are needed to evaluate the impact of allergen avoidance. If a patient with difficult-to-treat OFG has a positive patch test and exposure to allergens in their diet, we would recommend a trial of allergen avoidance/elimination diet to facilitate a multimodal approach to improving control of this difficult condition.

  PublisherDOI

• Oral lichen planus treated with upadacitinib: A case series

  JAAD Case Reports · 2025-07-02

  articleOpen access
  PublisherDOI

• <i>Letter:</i> The Impact of Allergen Avoidance in Burning Mouth Syndrome: A Case Series

  Dermatitis · 2025-01-23

  letter
  PublisherDOI

• 61355 Durability of Methotrexate, Mycophenolate, Azathioprine, and Cyclosporine in the Treatment of Oral Lichen Planus

  Journal of the American Academy of Dermatology · 2025-09-01

  article
  PublisherDOI

• The association between skin allergy testing and oral squamous cell carcinoma in oral lichen planus: a retrospective cohort study

  Archives of Dermatological Research · 2025-01-09

  article
  PublisherDOI

• 0288 Direct immunofluorescence for oral lichen planus

  Journal of Investigative Dermatology · 2025-07-21

  articleOpen access
  PublisherOA PDFDOI

• Recurrence Rates of Keratinocyte Carcinoma Treated With Curettage Alone: A Retrospective Cohort and Interview Study

  Dermatologic Surgery · 2025-06-13 · 1 citations

  article

  BACKGROUND: In the treatment of keratinocyte carcinoma, curettage alone has been described as a simpler, less expensive, and quicker method than electrodessication and curettage; however, there are limited studies examining recurrence rates for such lesions. OBJECTIVE: To investigate the 5-year recurrence rates of keratinocyte carcinoma treated with curettage alone and compare these results to previously reported recurrence rates for electrodessication and curettage. PATIENTS AND METHODS: A retrospective cohort and interview study determined 5-year recurrence rates for 1,853 total lesions treated with curettage alone using chart review data and patient phone calls. RESULTS: This study yielded a per-protocol 5-year recurrence rate of 2.41% for BCCs, 4.52% for SCCs, and an average of 3.71% across both types of keratinocyte carcinoma. Lesions on the head and neck displayed a significantly greater recurrence rate of 7.18% when treated with curettage alone. CONCLUSION: Curettage alone provides comparable efficacy in curing keratinocyte carcinoma when compared with electrodessication and curettage.

  PublisherDOI

• Durability of Conventional Immunosuppressants in the Treatment of Oral Lichen Planus.

  PubMed · 2025-12-01

  article

  BACKGROUND: Oral lichen planus (OLP) is an inflammatory disease involving the oral mucosa. It affects roughly 0.5% to 2% of the global population and has an associated risk of oral squamous cell carcinoma. Treatment of moderate to severe OLP often requires immunosuppression. The durability of immunosuppressive medication is currently unknown and is important for understanding therapeutic testing needs. OBJECTIVE: We investigated traditional immunosuppressive drug survival in patients with OLP and evaluated potential discontinuation factors. METHODS: We retrospectively analyzed patients with OLP treated with methotrexate, mycophenolate, azathioprine, or cyclosporine. Time to medication discontinuation was evaluated using the Kaplan-Meier estimator, and Cox proportional hazards regression was used to compare the risk of discontinuing a medication between medications and across patient demographic and disease factors. RESULTS: We identified 125 treatment periods with mycophenolate (n=58), methotrexate (n=34), azathioprine (n=19), or cyclosporine (n=14). Most patients had erosive disease (92%), and median time (IQR) to discontinuation due to adverse events or inefficacy was 9.43 months (6.51-16.1). Overall, only cyclosporine was associated with higher risk of discontinuation compared to methotrexate (hazard ratio [HR]: 2.94; 95% confidence interval [CI]: 1.32-6.45). There was no evidence for risk differences across age or sex for the overall cohort. Within individual medication groups, age was associated with a small increased risk of discontinuing mycophenolate (HR: 1.05; 95% CI: 1.00-1.10) and a small decreased risk in cyclosporine (HR=0.94, 95% CI: 0.89-0.99). Otherwise, no demographic factors were associated with discontinuation. Treatment success was reported 8 times. DISCUSSION: Immunosuppressive medications were frequently discontinued after short time periods, and few were discontinued due to success. These data highlight the need for better systemic therapy in OLP.

  Publisher

Frequent coauthors

• John J. Zone

  24 shared

• Mark D. Herron

  11 shared

• Elliott Herron

  Pomona College

  10 shared

• Aly Karsan

  BC Cancer Agency

  10 shared

• Fred Wong

  9 shared

• D. Powell

  University of Utah

  8 shared

• Aaron M. Secrest

  University of Utah

  7 shared

• Harry R. Hill

  University of Utah

  6 shared

Education

• M.D.

  University of Washington

• Other

  University of Utah